FDA Recognizes March Biosciences’ MB-105 with RMAT Status
By Daniella Parra March Biosciences said that the FDA granted regenerative medicine advanced therapy its first-in-class CD5-targeted CAR-T cell therapy for relapsed or refractory CD5-positive T-cell...
